Name | No. | For Patients with | Purpose |
---|---|---|---|
MK6482-012 | 21-18 | Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
The goal of this study is to Evaluate Efficacy and Safety of |
DSSG Group: Genitourinary
SABRE
Name | No. | For Patients with | Purpose |
---|---|---|---|
SABRE | 22-11 | Prostate Cancer being Treated with Stereotactic Body Radiotherapy |
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. |
Pivotal Study BP-007
Name | No. | For Patients with | Purpose |
---|---|---|---|
Pivotal Study BP-007 | 22-10 | For Patients who previously participated in the BP-007 clinical study |
The main purpose of this post marketing clinical follow up is to assess late toxicity and quality of life in subjects who participated in BP-007 clinical study. |
MK3475-365
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-365 | 21-20 | Metastatic Castrate Resistant Prostate Cancer (mCRPC). |
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). |
MK6482-011
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK6482-011 | 21-17 | Advanced Renal Cell Carcinoma (RCC) with clear cell component after prior therapy |
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. |
IMvigor011 B042843
Name | No. | For Patients with | Purpose |
---|---|---|---|
IMvigor011 B042843 | 21-38 | High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011) |
The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy. |
MK6482-022
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK6482-022 | 21-37 | Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy |
The purpose of this study is to assess the efficacy and safety of oral Belzutifan (MK-6482) plus intravenous (IV) Pembrolizumab (MK-3475) compared to placebo plus Pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. |
DASL HiCaP
Name | No. | For Patients with | Purpose |
---|---|---|---|
DASL HiCaP | CTRIAL-IE 19-32 | Either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy. |
Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting. |
IRONMAN: International Registry for Men with Advanced Prostate Cancer
Name | No. | For Patients with | Purpose |
---|---|---|---|
IRONMAN: International Registry for Men with Advanced Prostate Cancer | CTRIAL-IE 17-30 | Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) |
The purpose of this study is to create an international, population-based, |
PEACE III
Name | No. | For Patients with | Purpose |
---|---|---|---|
PEACE III | CTRIAL-IE 16-21 | asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone |
The purpose of this study is to find out whether the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) shows better activity against Xtandi® alone (enzalutamide) in metastatic prostate cancer and if the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) is safe. |